Oncology · Phase 2-3 · pulled 2026-11-06

Prostate cancer: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of prostate cancer (last 12 years), plus 300 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Prostate cancer: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Johns Hopkins University Baltimore, United States · 18 spellings merged	23 13 completed, 10 terminated	NCT03716739 NCT04037358 NCT04019964 6 trials with titles NCT03716739 Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency completed 2025-07-16 NCT04037358 RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers completed 2025-07-15 NCT04019964 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer completed 2025-07-03 NCT05946603 IS-002 Phase 2 Prostate Cancer Study completed 2025-05-23 NCT05366842 Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care terminated 2025-04-25 Stop reason on the record: “The sponsor was unable to produce and provide the study material (stravix)” NCT05551117 A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors terminated 2025-01-23 Stop reason on the record: “Business reasons”	2025-07-16	17 NCT02452008 NCT07225946 NCT07164443 NCT03047135	88
2	Carolina Urologic Research Center Myrtle Beach, United States · 4 spellings merged	21 11 completed, 10 terminated	NCT06395753 NCT03834493 NCT04191096 6 trials with titles NCT06395753 A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer completed 2026-07-22 NCT03834493 Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) terminated 2026-06-08 Stop reason on the record: “The study stopped due to futility” NCT04191096 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) terminated 2026-04-08 Stop reason on the record: “The study stopped due to futility” NCT05005728 XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer completed 2025-06-10 NCT06235099 Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer completed 2025-02-18 NCT05617040 Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer terminated 2025-02-05 Stop reason on the record: “The trial was discontinued following completion of the Phase 1 portion. This discontinuation was not based on safety concerns.”	2026-07-22	24 NCT03395197 NCT04821622 NCT04720157 NCT07723248	80
3	Washington University School of Medicine St Louis, United States · 15 spellings merged	17 11 completed, 6 terminated	NCT04037254 NCT06235099 NCT05617040 6 trials with titles NCT04037254 Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring completed 2025-12-23 NCT06235099 Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer completed 2025-02-18 NCT05617040 Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer terminated 2025-02-05 Stop reason on the record: “The trial was discontinued following completion of the Phase 1 portion. This discontinuation was not based on safety concerns.” NCT05075577 EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC terminated 2025-01-14 Stop reason on the record: “Study was terminated early due to a lack of improved efficacy.” NCT03939689 I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). completed 2024-09-24 NCT05407311 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE) completed 2024-05-13	2025-12-23	28 NCT05546268 NCT03866382 NCT04720157 NCT07225946	86
4	MD Anderson Cancer Center Houston, United States · 14 spellings merged	16 10 completed, 6 terminated	NCT04689828 NCT05848011 NCT04742361 6 trials with titles NCT04689828 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer completed 2026-09-09 NCT05848011 A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer completed 2026-03-16 NCT04742361 Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer completed 2025-05-05 NCT03939689 I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). completed 2024-09-24 NCT04381832 Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer completed 2024-08-30 NCT06065059 Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors terminated 2024-05-22 Stop reason on the record: “Terminated due to safety”	2026-09-09	31 NCT05546268 NCT06782555 NCT03972657 NCT04720157	90
5	University of California, San Francisco San Francisco, United States · 13 spellings merged	16 9 completed, 7 terminated	NCT04335682 NCT03503344 NCT03910660 6 trials with titles NCT04335682 Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide completed 2026-05-01 NCT03503344 Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer completed 2025-10-31 NCT03910660 A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. completed 2025-08-31 NCT05946603 IS-002 Phase 2 Prostate Cancer Study completed 2025-05-23 NCT04716725 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer terminated 2025-04-30 Stop reason on the record: “Low accrual” NCT05917470 A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. terminated 2024-09-12 Stop reason on the record: “Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients wit”	2026-05-01	16 NCT07287150 NCT04497844 NCT03748641 NCT06551324	88
6	Dana Farber Cancer Institute Boston, United States · 4 spellings merged	15 10 completed, 5 terminated	NCT04689828 NCT04335682 NCT05848011 6 trials with titles NCT04689828 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer completed 2026-09-09 NCT04335682 Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide completed 2026-05-01 NCT05848011 A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer completed 2026-03-16 NCT04751929 Abemaciclib With or Without Atezolizumab for mCRPC completed 2025-11-06 NCT03716739 Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency completed 2025-07-16 NCT03568656 Study to Evaluate CCS1477 in Advanced Tumours completed 2025-07-06	2026-09-09	20 NCT05546268 NCT04720157 NCT03767244 NCT07164443	91
7	Memorial Sloan Kettering Cancer Center New York, United States · 16 spellings merged	15 7 completed, 8 terminated	NCT04689828 NCT05133440 NCT04019327 6 trials with titles NCT04689828 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer completed 2026-09-09 NCT05133440 A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones completed 2026-04-27 NCT04019327 A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer terminated 2025-12-04 Stop reason on the record: “Study terminated by sponsor” NCT05588609 Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers terminated 2025-07-03 Stop reason on the record: “Merus terminated the study early due to changes in organizational priorities.” NCT05946603 IS-002 Phase 2 Prostate Cancer Study completed 2025-05-23 NCT05075577 EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC terminated 2025-01-14 Stop reason on the record: “Study was terminated early due to a lack of improved efficacy.”	2026-09-09	40 NCT05546268 NCT06986083 NCT04497844 NCT05100472	76
8	Karmanos Cancer Institute Detroit, United States · 5 spellings merged	15 8 completed, 7 terminated	NCT05059236 NCT05551117 NCT05917470 6 trials with titles NCT05059236 A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. completed 2026-06-15 NCT05551117 A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors terminated 2025-01-23 Stop reason on the record: “Business reasons” NCT05917470 A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. terminated 2024-09-12 Stop reason on the record: “Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients wit” NCT03570619 Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations completed 2024-03-26 NCT03834519 Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) completed 2024-01-27 NCT03834506 Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) completed 2023-07-18	2026-06-15	3 NCT06855277 NCT04585750 NCT06785636	85
9	Urology San Antonio San Antonio, United States · 5 spellings merged	15 9 completed, 6 terminated	NCT06235099 NCT05605964 NCT04179864 6 trials with titles NCT06235099 Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer completed 2025-02-18 NCT05605964 Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate completed 2024-12-31 NCT04179864 A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer terminated 2024-11-04 Stop reason on the record: “The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study.” NCT03850795 HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) terminated 2024-06-28 Stop reason on the record: “Terminated by Sponsor for various factors including prolonged duration and enrollment challenges” NCT05407311 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE) completed 2024-05-13 NCT04382898 PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) terminated 2024-01-23 Stop reason on the record: “Sponsor decision”	2025-02-18	8 NCT04821622 NCT06235151 NCT02319837 NCT06991556	84
10	Comprehensive Cancer Centers of Nevada Las Vegas, United States · 9 spellings merged	14 7 completed, 7 terminated	NCT03834493 NCT04191096 NCT06056791 6 trials with titles NCT03834493 Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) terminated 2026-06-08 Stop reason on the record: “The study stopped due to futility” NCT04191096 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) terminated 2026-04-08 Stop reason on the record: “The study stopped due to futility” NCT06056791 Study of INKmune in Patients With mCRPC (CaRe Prostate) completed 2025-09-10 NCT05005728 XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer completed 2025-06-10 NCT03934840 CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone completed 2025-04-03 NCT04179864 A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer terminated 2024-11-04 Stop reason on the record: “The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study.”	2026-06-08	9 NCT06136624 NCT03866382 NCT03748641 NCT06925737	84
11	University of Chicago Chicago, United States · 15 spellings merged	14 6 completed, 8 terminated	NCT04335682 NCT04191096 NCT05005728 6 trials with titles NCT04335682 Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide completed 2026-05-01 NCT04191096 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) terminated 2026-04-08 Stop reason on the record: “The study stopped due to futility” NCT05005728 XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer completed 2025-06-10 NCT03934840 CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone completed 2025-04-03 NCT03939689 I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). completed 2024-09-24 NCT04060394 Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC completed 2024-03-30	2026-05-01	25 NCT02452008 NCT06136624 NCT03866382 NCT04720157	81
12	Associated Medical Professionals Syracuse, United States · 12 spellings merged	13 8 completed, 5 terminated	NCT05059236 NCT03834493 NCT04191096 6 trials with titles NCT05059236 A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. completed 2026-06-15 NCT03834493 Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) terminated 2026-06-08 Stop reason on the record: “The study stopped due to futility” NCT04191096 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) terminated 2026-04-08 Stop reason on the record: “The study stopped due to futility” NCT05605964 Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate completed 2024-12-31 NCT04179864 A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer terminated 2024-11-04 Stop reason on the record: “The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study.” NCT04060394 Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC completed 2024-03-30	2026-06-15	10 NCT03395197 NCT04497844 NCT04557059 NCT07832292	85
13	University of Michigan Rogel Cancer Center Ann Arbor, United States · 12 spellings merged	12 7 completed, 5 terminated	NCT05708950 NCT03939689 NCT03570619 6 trials with titles NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) completed 2025-12-18 NCT03939689 I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). completed 2024-09-24 NCT03570619 Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations completed 2024-03-26 NCT04032704 A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors terminated 2023-11-28 Stop reason on the record: “Study closed due to portfolio prioritization” NCT03556904 FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE) completed 2023-07-28 NCT05177770 Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer terminated 2023-04-05 Stop reason on the record: “The study was terminated for strategic reasons, not due to any safety concerns.”	2025-12-18	12 NCT07164443 NCT06925737 NCT03367702 NCT02465060	90
14	Tower Urology Los Angeles, United States · 2 spellings merged	11 10 completed, 1 terminated	NCT06395753 NCT05059236 NCT06235099 6 trials with titles NCT06395753 A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer completed 2026-07-22 NCT05059236 A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. completed 2026-06-15 NCT06235099 Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer completed 2025-02-18 NCT05605964 Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate completed 2024-12-31 NCT05407311 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE) completed 2024-05-13 NCT05249127 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA) completed 2023-08-08	2026-07-22	1 NCT06235151	98
15	Gustave Roussy Villejuif, France · 8 spellings merged	11 8 completed, 3 terminated	NCT03834493 NCT05848011 NCT03568656 6 trials with titles NCT03834493 Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) terminated 2026-06-08 Stop reason on the record: “The study stopped due to futility” NCT05848011 A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer completed 2026-03-16 NCT03568656 Study to Evaluate CCS1477 in Advanced Tumours completed 2025-07-06 NCT05551117 A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors terminated 2025-01-23 Stop reason on the record: “Business reasons” NCT03518606 Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours completed 2024-12-19 NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors terminated 2024-11-29 Stop reason on the record: “Due to lack of expected efficacy shown at the time of the interim analysis”	2026-06-08	18 NCT07287150 NCT03395197 NCT04821622 NCT06136624	87
16	Northwestern University Chicago, United States · 3 spellings merged	11 5 completed, 6 terminated	NCT04335682 NCT04037254 NCT03934840 6 trials with titles NCT04335682 Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide completed 2026-05-01 NCT04037254 Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring completed 2025-12-23 NCT03934840 CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone completed 2025-04-03 NCT05605964 Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate completed 2024-12-31 NCT04381832 Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer completed 2024-08-30 NCT04383210 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors terminated 2024-02-28 Stop reason on the record: “Business decision”	2026-05-01	16 NCT02452008 NCT03866382 NCT04720157 NCT05691465	78
17	Centre Hospitalier de l'Université de Montréal Montreal, Canada · 21 spellings merged	10 4 completed, 6 terminated	NCT04655365 NCT03834493 NCT04191096 6 trials with titles NCT04655365 Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer. completed 2026-08-01 NCT03834493 Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) terminated 2026-06-08 Stop reason on the record: “The study stopped due to futility” NCT04191096 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) terminated 2026-04-08 Stop reason on the record: “The study stopped due to futility” NCT04736199 Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer completed 2026-01-23 NCT05075577 EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC terminated 2025-01-14 Stop reason on the record: “Study was terminated early due to a lack of improved efficacy.” NCT03764540 Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide terminated 2024-12-31 Stop reason on the record: “The cabazitaxel was recently approved by the regulatory authorities for mCRPCa”	2026-08-01	20 NCT07287150 NCT03395197 NCT04821622 NCT06136624	84
18	Moffitt Cancer Center Tampa, United States · 10 spellings merged	10 5 completed, 5 terminated	NCT03543189 NCT03834493 NCT03910660 6 trials with titles NCT03543189 Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy completed 2026-06-19 NCT03834493 Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) terminated 2026-06-08 Stop reason on the record: “The study stopped due to futility” NCT03910660 A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. completed 2025-08-31 NCT05075577 EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC terminated 2025-01-14 Stop reason on the record: “Study was terminated early due to a lack of improved efficacy.” NCT03570619 Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations completed 2024-03-26 NCT04383210 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors terminated 2024-02-28 Stop reason on the record: “Business decision”	2026-06-19	10 NCT03972657 NCT07164443 NCT02465060 NCT05946213	84
19	Hopital Foch Suresnes, France · 8 spellings merged	10 5 completed, 5 terminated	NCT03834493 NCT04191096 NCT05848011 6 trials with titles NCT03834493 Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) terminated 2026-06-08 Stop reason on the record: “The study stopped due to futility” NCT04191096 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) terminated 2026-04-08 Stop reason on the record: “The study stopped due to futility” NCT05848011 A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer completed 2026-03-16 NCT03568188 Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer completed 2026-02-09 NCT05551117 A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors terminated 2025-01-23 Stop reason on the record: “Business reasons” NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors terminated 2024-11-29 Stop reason on the record: “Due to lack of expected efficacy shown at the time of the interim analysis”	2026-06-08	7 NCT03395197 NCT04497844 NCT06551324 NCT06925737	80
20	University of Virginia Cancer Center Charlottesville, United States · 8 spellings merged	10 4 completed, 6 terminated	NCT05848011 NCT04019327 NCT05617040 6 trials with titles NCT05848011 A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer completed 2026-03-16 NCT04019327 A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer terminated 2025-12-04 Stop reason on the record: “Study terminated by sponsor” NCT05617040 Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer terminated 2025-02-05 Stop reason on the record: “The trial was discontinued following completion of the Phase 1 portion. This discontinuation was not based on safety concerns.” NCT05551117 A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors terminated 2025-01-23 Stop reason on the record: “Business reasons” NCT03939689 I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). completed 2024-09-24 NCT04382898 PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) terminated 2024-01-23 Stop reason on the record: “Sponsor decision”	2026-03-16	11 NCT06136624 NCT04720157 NCT07213674 NCT06136650	75
21	Icahn School of Medicine at Mount Sinai New York, United States · 14 spellings merged	9 8 completed, 1 terminated	NCT04689828 NCT06395753 NCT05059236 6 trials with titles NCT04689828 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer completed 2026-09-09 NCT06395753 A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer completed 2026-07-22 NCT05059236 A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. completed 2026-06-15 NCT05848011 A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer completed 2026-03-16 NCT03686683 Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer completed 2023-03-10 NCT03572387 A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment completed 2022-07-08	2026-09-09	14 NCT04497844 NCT03972657 NCT03748641 NCT06931340	97
22	Hospital Universitari Vall d'Hebron Barcelona, Spain · 10 spellings merged	9 5 completed, 4 terminated	NCT06395753 NCT03568656 NCT04332744 6 trials with titles NCT06395753 A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer completed 2026-07-22 NCT03568656 Study to Evaluate CCS1477 in Advanced Tumours completed 2025-07-06 NCT04332744 Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) completed 2025-05-06 NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors terminated 2024-11-29 Stop reason on the record: “Due to lack of expected efficacy shown at the time of the interim analysis” NCT05458856 Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate completed 2024-07-08 NCT04408924 Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer completed 2023-06-02	2026-07-22	7 NCT03395197 NCT04821622 NCT06122584 NCT06353386	82
23	Fred Hutch/University of Washington Cancer Consortium Seattle, United States	9 2 completed, 7 terminated	NCT05960578 NCT06661902 NCT04336943 6 trials with titles NCT05960578 Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study terminated 2026-04-14 Stop reason on the record: “The trial was ended sooner than expected due to a combination of factors, including slow accrual, lower than anticipated benefit to patients, and loss of funding from the study sponsor.” NCT06661902 Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial completed 2026-01-27 NCT04336943 Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load terminated 2025-06-06 Stop reason on the record: “Slow accrual” NCT03442556 Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency terminated 2025-06-04 Stop reason on the record: “Terminated due to insufficient funding” NCT03516812 Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer completed 2024-04-12 NCT04951492 Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma terminated 2023-10-15 Stop reason on the record: “Withdrawal of funding”	2026-04-14	2 NCT07466498 NCT07698535	75
24	City of Hope Duarte, United States · 9 spellings merged	9 5 completed, 4 terminated	NCT04191096 NCT04037254 NCT05005728 6 trials with titles NCT04191096 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) terminated 2026-04-08 Stop reason on the record: “The study stopped due to futility” NCT04037254 Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring completed 2025-12-23 NCT05005728 XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer completed 2025-06-10 NCT03939689 I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). completed 2024-09-24 NCT05553639 HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer terminated 2024-04-29 Stop reason on the record: “Decision by the company to terminate the H-300-001 study early for non-safety related reasons.” NCT04742959 Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors completed 2024-02-20	2026-04-08	20 NCT05691465 NCT06925737 NCT05751434 NCT07210086	83
25	Hospital Universitario 12 de Octubre Madrid, Spain · 9 spellings merged	9 4 completed, 5 terminated	NCT04191096 NCT05848011 NCT04332744 6 trials with titles NCT04191096 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) terminated 2026-04-08 Stop reason on the record: “The study stopped due to futility” NCT05848011 A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer completed 2026-03-16 NCT04332744 Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) completed 2025-05-06 NCT05551117 A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors terminated 2025-01-23 Stop reason on the record: “Business reasons” NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors terminated 2024-11-29 Stop reason on the record: “Due to lack of expected efficacy shown at the time of the interim analysis” NCT04179864 A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer terminated 2024-11-04 Stop reason on the record: “The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study.”	2026-04-08	12 NCT07287150 NCT03395197 NCT06136624 NCT06551324	74

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Prostate cancer: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Michael Schweizer Fred Hutch/University of Washington Cancer Consortium	4	NCT04951492 NCT04336943 NCT03999515 NCT03516812	PMID 39486241 Biomaterials advances, 2024 · Medium match PMID 37609284 Research square, 2025 · High match PMID 29017058 Cancer cell, 2017 · High match
2	Andrei Iagaru Stanford Cancer Institute Palo Alto	4	NCT03698370 NCT04264208 NCT03949517 NCT03809078	PMID 42399196 European urology, 2026 · Medium match
3	Clint Bahler Indiana University	3	NCT06849544 NCT06434909 NCT03429244	PMID 42101556 Journal of racial and ethnic health disparities, 2026 · High match PMID 40616986 Clinical imaging, 2025 · High match PMID 36898362 Journal of the National Comprehensive Cancer Network : JNCCN, 2023 · High match
4	Alexander Philipovskiy Florida Cancer Specialists & Research Institute	3	NCT06257758 NCT04037358 NCT03406858	No paper matched at High or Medium confidence
5	Jinming Zhang The First Medical Center of the General Hospital of the Chinese People's Liberation Army	3	NCT06472531 NCT04685811 NCT03515577	PMID 42962342 Biomaterials, 2026 · Medium match PMID 42957205 Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026 · Medium match PMID 42927141 BJR open, 2026 · High match
6	Michael M Graham University of Iowa	3	NCT03822845 NCT03689582 NCT03554317	No paper matched at High or Medium confidence
7	Stephen Freedland Cedars-Sinai Medical Center	2	NCT03824652 NCT03679260	PMID 42934071 European urology, 2026 · Medium match PMID 41578109 Journal of general internal medicine, 2026 · High match PMID 39483875 Research square, 2026 · High match
8	Zin Myint University of Kentucky	2	NCT05478239 NCT04616547	PMID 39859392 International journal of molecular sciences, 2025 · High match PMID 39793235 Clinical genitourinary cancer, 2025 · High match PMID 39521639 European urology oncology, 2025 · High match
9	Cheol Kwak Department of Urology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea	2	NCT06490328 NCT03535675	PMID 42683858 Investigative and clinical urology, 2026 · High match PMID 42561994 Lancet (London, England), 2026 · High match PMID 42405706 Investigative and clinical urology, 2026 · High match
10	Andrew McDonald University of Alabama at Birmingham (UAB)	2	NCT04743934 NCT04298983	PMID 42313395 JAMA oncology, 2026 · High match PMID 40516971 Seminars in radiation oncology, 2025 · High match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.